Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
KTPasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp. (KTTA)

NASDAQ Capital Market · Currency in USD
$0.40 ▼ -0.04 (-9.05%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.40 ▼ -0.01 (-2.40%)
After hours: Oct 23, 4:19 PM ET

Summary

Previous Close
$0.45
Open
$0.45
Day's Range
$0.35 – $0.45
52 Week Range
$0.28 – $2.06
Volume
1,533,405
Avg. Volume
602,887
Market Cap
$13.53M
Beta (5Y Monthly)
0.29
PE Ratio (TTM)
--
EPS (TTM)
-$3.03
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.00

Profile: Pasithea Therapeutics Corp.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Tiago Reis Marques

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.21 · Revenue est. $200.00K
DateEst.Actual
Aug 14, 2026-$0.16-$0.16Beat
May 15, 2026-$0.45-$0.12Beat
Mar 30, 2026-$0.18-$0.89Miss
Nov 13, 2025-$0.18-$0.41Miss
Aug 14, 2025–-$0.66
May 15, 2025–-$1.61

Analyst view

Consensus price target
$3.00 ▲ +640.9%
Range $3.00 – $3.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on KTTA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.